Novavax's (NVAX +2.3%) vaccine for respiratory syncytial virus (RSV) appears to have performed...


Novavax's (NVAX +2.3%) vaccine for respiratory syncytial virus (RSV) appears to have performed well in a Phase I trial of elderly people, with all 220 subjects exhibiting antibody responses against RSV at 28 and 56 days. With subjects also receiving a flu vaccine, the data paves the way for a combo drug (PR). Meanwhile, Novavax has started a Phase I trial for a vaccine for a strain of bird flu called A/Anhui/1/13-like A(H7N9). The trial will recruit 280 adults (PR).

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs